Financial results of Q2 2024 Group net sales up organically by 1.7% to € 5.4 billion EBITDA pre down 0.8% organically to € 1...
– Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, incre...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29...
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted D...
net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entr...
Financial results of Q1 2024 Healthcare with strong performance Electronics increases sales and earnings organically, driven by higher demand for semic...
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 bil...
First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023...
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...
Broad-based performance drives sales, profits and earnings growth: Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID Vaccines sales +16...
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 Net ...
Gilead Sciences Announces First Quarter 2024 Financial Results Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the first quarter ended March 30, ...
Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 20...
© 2024 Biopharma Boardroom. All Rights Reserved.